PDF
ePub
Citation
Print
Abstract
Purpose
Chronic bacterial prostatitis (CBP) is the most common urological disease in adult males, with antibiotic therapy being the gold standard for its treatment. However, long-term therapy results in many side effects as well as bacterial resistance. For these reasons, there is a need for a new treatment modality to replace traditional antibiotic therapy. Lycopene, an extract of tomatoes, has antioxidant effects against various bacteria and synergistic effects with antibiotics. We evaluate the synergistic effects of lycopene on the treatment of CBP in an animal model.
Materials and Methods
Forty five rats demonstrating CBP were randomly divided into 4 groups; the control, lycopene, ciprofloxacin and lycopene with ciprofloxacin groups. All drug treatments were conducted over a period of 2 weeks. After treatment, the results were analyzed, with the microbiological cultures and histological findings of the prostate and urine samples compared with the control group and between each group.
Results
The uses of ciprofloxacin, and lycopene with ciprofloxacin showed statistically significant decreases in bacterial growth and improvements in prostatic inflammation compared with the control group (p<0.05). The lycopene with ciprofloxacin group showed a statistically significant decrease in bacterial growth and improvements in prostatic inflammation compared with the ciprofloxacin group (p<0.05).
Conclusions
These results suggest that lycopene may be an effective material in the treatment of CBP. Especially, the combination treatment of lycopene and ciprofloxacin has synergistic effects. Therefore, it is suggest that the combination of lycopene and ciprofloxacin may be effective in the treatment of CBP, and with a higher success rate.
Figures and Tables
Fig. 1
Prostate section of a chronic bacterial prostatitis rat, obtained 2 weeks after each treatment (H&E, Bar=100µm). (A) The acinar structures are severely atrophied and obliterated. Marked chronic inflammatory cell infiltration and interstitial fibrosis are seen (Group I). (B) The acinar structures are moderately atrophied and obliterated. Moderate chronic inflammatory cell infiltration and interstitial fibrosis are seen (Group II). (C) The acinar structures are mildly shrunken, with mild lymphocytic infiltration and fibrosis in the interstitial space (Group III). (D) The acinar structures have a nearly normal appearance, with mild lymphocytic infiltration and focal fibrosis in the interstitial space (Group IV).
Fig. 2
Severity scores of chronic inflammatory cell infiltrations, acinar changes and interstitial fibrosis in each group. The values, expressed the means±SD, are compared with that of the control group. *: p<0.05, compared with the control group, †: p<0.05, compared with the ciprofloxacin group, SD: standard deviation.
References
1. Pfau A. Prostatitis. A continuing enigma. Urol Clin North Am. 1986. 13:695–715.
2. Nickel JC, Olson ME, Costerton JW. Rat model of experimental bacterial prostatitis. Infection. 1991. 19:Suppl 3. 126–130.
3. Nickel JC. Antibiotics for bacterial prostatitis. J Urol. 2000. 163:1407.
4. Ansari MS, Ansari S. Lycopene and prostate cancer. Future Oncol. 2005. 1:425–430.
5. Wane D, Lengacher CA. Intergrative review of lycopene and breast cancer. Oncol Nurs Forum. 2006. 33:127–137.
6. Hsiao G, Wang Y, Tzu NH, Fong TH, Shen MY, Lin KH, et al. Inhibitory effects of lycopene on in vitro platelet activation and in vivo prevention of thrombus formation. J Lab Clin Med. 2005. 146:216–226.
7. Vicari E, Rubino C, De Palma, Longo G, Lauretta M, Consoli S, et al. Antioxidant therapeutic effeciency after the use of carnitine in infertile patients with bacterial or non bacterial prostato-vesiculo-epididymitis. Arch Ital Urol Androl. 2001. 73:15–25.
8. Shahed AR, Shoskes DA. Oxidative stress in prostatic fluid of patients with chronic pelvic pain syndrome. J Androl. 2000. 21:669–675.
9. Lee YS, Shin MS, Cho YH. Experimental animal model of bacterial prostatitis. Korean J Urol. 2001. 42:636–641.
10. Seo SI, Lee SJ, Kim JC, Choi YJ, Kim SW, Hwang TK, et al. Effects of androgen deprivation on chronic bacterial prostatitis in a rat model. Int J Urol. 2003. 10:485–491.
11. Nickel JC, Olson ME, Barabas A, Benediktsson H, Dasgupta MK, Costerton JW. Pathogenesis of chronic bacterial prostatitis in an animal model. Br J Urol. 1990. 66:47–54.
12. Cho YH, Lee SJ, Lee JY, Kim SW, Lee CB, Lee WY, et al. Antibacterial effect of intraprostatic zinc injection in a rat model of chronic bacterial prostatitis. Int J Antimicrob Agents. 2002. 19:576–582.
13. Jantos C, Altmannsberger M, Weidner W, Schiefer HG. Acute and chronic bacterial prostatitis due to E-coli. Description of an animal model. Urol Res. 1990. 18:207–211.
14. Moon TD. Questionnaire survey of urologist and primary care physicians' diagnostic and treatment practices for prostatitis. Urology. 1997. 50:543–547.
15. Terai A, Yamamoto S, Mitsumori K, Okada Y, Kurazono H, Takeda Y, et al. Escherichia coli virulence factors and serotypes in acute bacterial prostatitis. Int J Urol. 1997. 4:289–294.
16. Neal DE Jr, Moon TD. Use of terazosin in prostatodynia and validation of a symptom score questionnaire. Urology. 1994. 43:460–465.
17. Winningham DG, Nemoy NJ, Stamey TA. Diffusion of antibiotics from plasma into prostatic fluid. Nature. 1968. 219:139–143.
18. Stamey TA, Meares EM Jr, Winningham DG. Chronic bacterial prostatitis and diffusion of drugs into prostatic fluid. J Urol. 1970. 103:187–194.
19. Herzog A, Siler U, Spitzer N, Seifert N, Denelavas A, Hunziker PB, et al. Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate. FASEB J. 2005. 19:272–274.
20. Kaplan SA. Lycopene: modes of action to promote prostate health. J Urol. 2005. 174:679.
21. Wertz K, Siler U, Goralczyk R. Lycopene: modes of action to promote prostate health. Arch Biochem Biophys. 2004. 430:127–134.
22. Reifen R, Nur T, Matas Z, Halpern Z. Lycopene supplementation attenuates the inflammatory status of colitis in a rat model. Int J Vitam Nutr Res. 2001. 71:347–351.
XML Download